Implantable Cardioverter Defibrillator Improves Survival in Patients with Heart Failure

Institution:

School of Medicine and Dentistry at the University of Rochester Medical Center

Researchers:

Arthur J. Moss, M.D., Bradford C. Berk, M.D., Ph.D. Distinguished Professor of Cardiology, University of Rochester School of Medicine and Dentistry

Impact:

Moss led the MADIT (Multicenter Automatic Defibrillator Implantation Trial) series of trials that demonstrated that preventive therapy with an implantable cardioverter defibrillator or ICD – a device that detects potentially fatal arrhythmias and shocks the heart back into a normal rhythm – significantly reduces the risk of death in heart attack survivors. This finding changed medical guidelines nationwide and led to the use of ICDs in millions of patients.

Timeline:

The finding that ICDs reduce death and increase survival was published in the New England Journal of Medicine in 2002.